Cooper Co (CP60) Stock Price & Analysis
CP60 Stock Chart & Stats
- Day’s Range
- EUR 54.54 - EUR 54.70
- 52-Week Range
- EUR 44.51 - EUR 74.50
- Previous Close
- EUR 54.56
- Volume
- N/A
- Average Volume (3M)
- 43
- Market Cap
- EUR 10.37B
- Enterprise Value
- EUR 16.38B
- Total Cash (Recent Filing)
- EUR 154.70M
- Total Debt (Recent Filing)
- EUR 2.54B
- Price to Earnings (P/E)
- 20.8
- Beta
- 0.65
- Next Earnings
- Dec 03, 2026 (Est.)
- EPS Estimate
- 0.95
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Solid Revenue Growth
Sustained revenue expansion indicates continued demand across Cooper’s vision-care and women’s-health businesses. A growing top line provides a durable base for operating leverage, supports investment in product development and commercial coverage, and can strengthen the company’s position over multiple quarters.
Fertility Market Share Gains
Broad-based fertility growth and reported market-share gains suggest CooperSurgical is benefiting from durable industry drivers rather than a single product cycle. Clinic wins, genomics demand and expanding services can deepen customer relationships and support recurring growth as treatment access increases.
Conservative Balance Sheet
Moderate and improving leverage gives Cooper financial flexibility to fund research, commercial expansion and targeted capital returns without relying heavily on additional debt. The stronger equity base also improves resilience if operating conditions remain uneven across vision care and fertility markets.
Bears Say
Weak Cash Conversion
The sharp deterioration in operating and free cash flow makes reported earnings less dependable as a measure of internally generated funding. If cash conversion remains weak, Cooper may have less capacity for innovation, acquisitions and capital returns, while working-capital or spending pressures could persist.
Leadership Transition
A CEO departure and interim operating structure introduce execution and strategic-continuity risk during a period that already requires improved commercial performance. The search process may delay decisions, disrupt accountability or alter priorities before a permanent leadership team is established.
Compressed Operating Margins
The large decline in operating margin shows that revenue growth has not translated consistently into profitability. Higher commercial investment, foreign-exchange pressure and other operating costs could keep earnings leverage subdued, limiting the benefit of sales growth until execution improves.
Cooper Co News
CP60 FAQ
What was Cooper Co’s price range in the past 12 months?
What is Cooper Co’s market cap?
When is Cooper Co’s upcoming earnings report date?
How were Cooper Co’s earnings last quarter?
Is Cooper Co overvalued?
Does Cooper Co pay dividends?
What is Cooper Co’s EPS estimate?
How many shares outstanding does Cooper Co have?
What happened to Cooper Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cooper Co?
What is the TipRanks Smart Score and how is it calculated?
Cooper Co Stock Smart Score
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White
- Employees
- 15,000
- Website
- www.coopercos.com
- Address
- 6101 Bollinger Canyon Road, San Ramon, CA, 94583, US
Cooper Co (CP60) Earnings & Revenues
CP60 Company Deck
CP60 Earnings Call
Earnings Call SentimentPositive
The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.
View all DE:CP60 earnings summariesCP60 Net sales Breakdown
- 67.05% CooperVision
- 32.95% CooperSurgical
CP60 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 5 | 7 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 8 | 0 | 4 |
